Caffeine is an important naturally occurring compound that can be degraded by bacteria. Excessive caffeine consumption is known to have some adverse problems. Previously, Leifsonia sp. strain SIU capable of degrading caffeine was isolated from agricultural soil. The bacterium was tested for its ability to degrade caffeine as the sole carbon and nitrogen source. The isolate was encapsulated in gellan gum and its ability to degrade caffeine in the presence of heavy metals was determined. Out of the nine heavy metals tested, Copper (Cu), Mercury (Hg), and Silver (Ag) had significant effects on caffeine degradation at 1mg/L. Therefore, the concentration of these heavy metals was varied from 0 -1 mg/L to see at what concentration each metal it has effect. Ag and Hg showed effect at 0.1 mg/L with caffeine degradation of 64.05 and 52.17% respectively, while Cu showed effect at 0.8 mg/L with caffeine degradation of 64.74%. These bacterium features make it an ultimate means for caffeine bioremediation. This is the first report of effect of heavy metals on caffeine degradation by immobilised Leifsonia sp. strain SIU.
Urothelial cell carcinoma (UCC) is the ninth most common cancer that accounts for 4.7% of all new cancer cases globally. UCC development and progression are due to complex and stochastic genetic programs. To study the cascades of molecular events underlying the poor prognosis that may lead to limited treatment options for advanced disease and resistance to conventional therapies in UCC, transcriptomics technology (RNA‐Seq), a method of analyzing the RNA content of a sample using modern high‐throughput sequencing platforms has been employed. Here, we review the principles of RNA‐Seq technology and summarize recent studies on human bladder cancer that employed this technique to unravel the pathogenesis of the disease, identify biomarkers, discover pathways and classify the disease state. We list the commonly used computational platforms and software that are publicly available for RNA‐Seq analysis. Moreover, we discussed the future perspectives for RNA‐Seq studies on bladder cancer and recommended the application of a new technology called single‐cell sequencing to further understand the disease.
Urothelial cell carcinoma (UCC) is the ninth most common cancer that accounts for 4.7% of all the new cancer cases globally. UCC development and progression are due to complex and stochastic genetic programmes. To study the cascades molecular events underlying the poor prognosis that are due to limited treatment options for advance disease and resistance to conventional therapies in UCC, transcriptomics technology (RNA-Seq), a method of analysing the RNA content of a sample using the modern high-throughput sequencing platforms has been employed to address these limitations. Here we review the principles of RNA-Seq technology and summarize the recent studies on human bladder cancer that employed this technique to unravel the pathogenesis of the disease, identify biomarkers, discover pathways and classify the disease state. We list the commonly used computational platforms and software that are publicly available for RNA-Seq analysis. Moreover, we discussed the future perspective for RNA-Seq studies on bladder cancer and recommend the application of new technology called single cell sequencing (scRNA-Seq) to further understand bladder cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.